| Literature DB >> 27472318 |
Michael H Kogut1, Christina L Swaggerty2, James Allen Byrd3, Ramesh Selvaraj4, Ryan J Arsenault5.
Abstract
Non-typhoidal Salmonella enterica induces an early, short-lived pro-inflammatory response in chickens that is asymptomatic of clinical disease and results in a persistent colonization of the gastrointestinal (GI) tract that transmits infections to naïve hosts via fecal shedding of bacteria. The underlying mechanisms that control this persistent colonization of the ceca of chickens by Salmonella are only beginning to be elucidated. We hypothesize that alteration of host signaling pathways mediate the induction of a tolerance response. Using chicken-specific kinomic immune peptide arrays and quantitative RT-PCR of infected cecal tissue, we have previously evaluated the development of disease tolerance in chickens infected with Salmonella enterica serovar Enteritidis (S. Enteritidis) in a persistent infection model (4-14 days post infection). Here, we have further outlined the induction of an tolerance defense strategy in the cecum of chickens infected with S. Enteritidis beginning around four days post-primary infection. The response is characterized by alterations in the activation of T cell signaling mediated by the dephosphorylation of phospholipase c-γ1 (PLCG1) that inhibits NF-κB signaling and activates nuclear factor of activated T-cells (NFAT) signaling and blockage of interferon-γ (IFN-γ) production through the disruption of the JAK-STAT signaling pathway (dephosphorylation of JAK2, JAK3, and STAT4). Further, we measured a significant down-regulation reduction in IFN-γ mRNA expression. These studies, combined with our previous findings, describe global phenotypic changes in the avian cecum of Salmonella Enteritidis-infected chickens that decreases the host responsiveness resulting in the establishment of persistent colonization. The identified tissue protein kinases also represent potential targets for future antimicrobial compounds for decreasing Salmonella loads in the intestines of food animals before going to market.Entities:
Keywords: JAK-STAT pathway; Salmonella; interferon-γ; kinome; phospholipase c
Mesh:
Substances:
Year: 2016 PMID: 27472318 PMCID: PMC5000605 DOI: 10.3390/ijms17081207
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Number of chickens positive for Salmonella Enteritidis ceca colonization for 2 weeks following challenge.
| Treatment Groups | Percent Positive for | |||
|---|---|---|---|---|
| Days post-challenge | ||||
| 4 | 7 | 10 | 14 | |
| Non-infected control | 0 | 0 | 0 | 0 |
| (0/50) | (0/50) | (0/50) | (0/50) | |
| Infected | 100 | 100 | 90 | 83 |
| (50/50) | (50/50) | (45/50) | (41/50) | |
Cecal Salmonella Enteritidis CFUs for 2 weeks following challenge.
| Treatment Groups | CFU of | |||
|---|---|---|---|---|
| Days post-challenge | ||||
| 4 | 7 | 10 | 14 | |
| Non-infected control | 0 | 0 | 0 | 0 |
| Infected | 5.398 ± 1.112 | 5.708 ± 1.341 | 4.342 ± 00.859 | 3.476 ± 1.472 |
KEGG Pathways generated by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING).
| 4 Days | 7 Days | 10 Days | 14 Days | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| GO ID | Pathway | # Peptides | # Peptides | # Peptides | # Peptides | Reference | ||||
| hsa04660 | T cell receptor signaling pathway | 26 | 3.09 × 10−18 | - | N/S | 9 | 2.9 × 10−5 | 11 | 6.93 × 10−7 | Here |
| hsa05130 | Pathogenic Escherichia coli infection | - | N/S | 2 | N/S | 4 | N/S | 4 | N/S | - |
| hsa04250 | TGF-β4 signaling pathway | 7 | 0.016 | - | N/S | - | N/S | - | N/S | [ |
| hsa04310 | Wnt signaling pathway | 13 | 0.0004 | 3 | N/S | - | N/S | 6 | 0.024 | [ |
| hsa05217 | Basal cell carcinoma | - | N/S | - | N/S | 2 | 0.338 | - | N/S | - |
| hsa04150 | mTOR signaling pathway | 13 | 4.83 × 10−10 | 2 | N/S | 5 | 1.32 × 10−3 | - | N/S | [ |
| hsa04630 | JAK-STAT signaling pathway | 23 | 4.13 × 10−12 | 1 | 3.8 × 10−2 | 6 | 2.14 × 10−4 | 6 | 2.9 × 10−4 | Here |
Peptides that displayed a significant change in phosphorylation state were input into the STRING database for each time point. Generated pathways involved in immune activation/suppression that displayed p-value of less than 0.05 (FDR corrected) are listed. # Peptides refers to number of peptides within the given pathway that were present within the peptide array data set. N/S indicates that the pathway is non-significant.
Peptides from the T cell receptor signaling pathway that displayed a statistically significant change in phosphorylation.
| T Cell Receptor Signaling Pathway | ||||||||
|---|---|---|---|---|---|---|---|---|
| Days Post Infection | ||||||||
| 4 | 7 | 10 | 14 | |||||
| Peptide | Fold Change | Fold Change | Fold Change | Fold Change | ||||
| Akt1 | 1.52 | 0.03 | - | - | - | - | - | - |
| Akt3 | 1.80 | 0.04 | - | - | - | - | - | - |
| Cbl Y728 | −1.97 | 0.03 | - | - | - | - | −1.23 | 0.03 |
| Cbl Y773 | 1.30 | 0.02 | - | - | - | - | - | - |
| CDC42 | 1.69 | 0.01 | - | - | - | - | - | - |
| IKK-β | −2.87 | 5.39 × 10−5 | - | - | −1.91 | 0.04 | - | - |
| FYN | - | - | - | - | −2.29 | 0.03 | - | - |
| GRB2 | - | - | - | - | −1.84 | 0.04 | - | - |
| GSK-3β | −2.25 | 0.002 | - | - | −2.45 | 0.02 | - | - |
| HRAS | −1.97 | 0.009 | - | - | - | - | - | - |
| ITK | −2.87 | 0.007 | - | - | - | - | 1.61 | 0.04 |
| Jun S59 | 3.60 | 0.0008 | - | - | - | - | - | - |
| Jun S69 | −3.39 | 0.0004 | - | - | - | - | - | - |
| MEK1 | −3.23 | 0.03 | - | - | - | - | - | - |
| MEK2 | 1.25 | 0.01 | - | - | - | - | - | - |
| MAP2K2 | −1.55 | 0.01 | - | - | - | - | - | - |
| MAP3K14 | 2.87 | 0.005 | - | - | - | - | 1.10 | 0.03 |
| MAPK3K7 | 2.71 | 0.02 | - | - | 4.48 | 0.01 | - | - |
| MAP3K8 | −1.40 | 0.02 | −2.13 | 0.01 | - | - | - | - |
| p38 MAPK (MAPK11) | −1.97 | 0.02 | - | - | - | - | - | |
| p38 MAPK (MAPK14) | - | - | - | - | - | - | −1.72 | 0.04 |
| ERK1 | −4.27 | 0.001 | - | - | 1.61 | 0.01 | - | - |
| NFATC1 | - | - | - | - | - | 1.96 | 0.01 | |
| NAFATC2 | 1.78 | 0.04 | - | - | - | - | - | - |
| NFATC3 | 2.24 | 0.01 | - | - | - | - | - | - |
| NFκB1 | −3.12 | 0.02 | - | - | - | −1.65 | 0.02 | |
| NFκB1A | −2.59 | 0.001 | - | - | −1.54 | 0.01 | −1.57 | 0.01 |
| PAK1 S198 | −1.41 | 0.04 | - | - | - | - | - | |
| PAK1 T212 | 5.36 | 0.001 | - | - | - | - | 1.05 | 0.02 |
| PAK1 T422 | −2.64 | 0.01 | - | - | - | - | - | - |
| PI3KR1 | 3.08 | 0.02 | - | - | - | - | - | - |
| PLCG1 | −2.79 | 0.001 | - | - | - | - | - | - |
| PRKCQ | −1.47 | 0.003 | - | - | - | - | - | - |
| PTPRC | - | - | - | - | −2.97 | 0.02 | - | - |
| RAF1 | −2.29 | 0.003 | - | - | - | - | 1.36 | 0.01 |
| SOS1 | 3.15 | 0.01 | - | - | 1.76 | 0.04 | 1.94 | 0.03 |
Peptides that displayed a p-value of less than 0.05 are listed.
Peptides from the JAK-STAT signaling pathway that displayed a statistically significant change in phosphorylation.
| JAK-STAT Signaling Pathway | ||||||||
|---|---|---|---|---|---|---|---|---|
| DAYS POST-INFECTION | ||||||||
| 4 | 7 | 10 | 14 | |||||
| Peptide | Fold Change | Fold Change | Fold Change | Fold Change | ||||
| AKT1 | 1.52 | 0.03 | - | - | - | - | - | - |
| AKT3 | 1.80 | 0.04 | - | - | - | - | - | - |
| Cbl | 1.29 | 0.02 | - | - | - | - | - | - |
| IFNAR1 | 1.88 | 0.003 | - | - | - | - | - | - |
| IFNGR1 | −1.53 | 0.01 | - | - | - | - | - | - |
| IL-10R-A | 5.10 | 0.03 | - | - | 2.72 | 0.03 | - | - |
| IL-2RB | 7.89 | 0.0003 | - | - | - | - | - | - |
| IL4R | 1.37 | 0.01 | - | - | 5.19 | 0.003 | - | - |
| IL-6R | −1.81 | 0.01 | - | - | - | - | - | - |
| IL7R | −6.10 | 0.001 | - | - | - | - | - | - |
| Jak2 | −3.11 | 0.004 | - | - | - | - | −1.69 | 0.05 |
| Jak3 | −3.69 | 0.002 | −1.68 | 0.02 | −18.74 | 0.0006 | - | - |
| PIK3R1 | 3.08 | 0.02 | - | - | - | - | - | - |
| PIM1 | −3.09 | 0.03 | - | - | - | - | 1.26 | 0.02 |
| SOS1 | 3.15 | 0.01 | - | - | 1.76 | 0.04 | 1.65 | 0.003 |
| STAT1 | 2.48 | 0.03 | - | - | - | - | −2.17 | 0.009 |
| STAT3 S728 | 2.44 | 0.03 | - | - | - | - | 1.94 | 0.03 |
| STAT3 Y706 | 1.99 | 0.04 | - | - | - | - | - | - |
| STAT4 | −2.73 | 0.05 | - | - | −7.52 | 0.04 | - | - |
| STAT5B Y699 | 3.33 | 0.028599 | - | - | - | - | - | - |
| STAT5B Y740 | 2.01 | 0.04 | - | - | −1.29 | 0.01 | ||
| STAT6 | 4.07 | 0.003 | - | - | −1.58 | 0.007 | - | - |
| TYK2 | 1.49 | 0.02 | - | - | - | - | - | - |
Peptides that displayed a p-value of less than 0.05 are listed.
Antibody array results.
| Antibody Array | Peptide Array | % Homology | ||||
|---|---|---|---|---|---|---|
| ID | Fold Change | ID | Fold Change | |||
| AMPK (Phospho-Thr174) | 2.05 | 0.02 | AMPK1 S173 | 4.23 | 0.03 | 100 |
| ATF2 (Phospho-Ser112/94) | −2.13 | 0.02 | ATF2 T72 | −2.88 | 0.005 | |
| Calmodulin (Phospho-Thr79/Ser81) | −1.48 | 0.01 | Calmodulin T80 | −1.53 | 0.04 | 100 |
| Calmodulin Y100 | −1.56 | 0.003 | ||||
| CAMK2-β/γ/Δ (Phospho-Thr287) | 1.17 | 0.01 | CAMK2-alpha T305 | 2.79 | 0.01 | 100 |
| CDC25C (Phospho-Thr48) | −1.54 | 0.03 | Cdc25A T510 | −1.99 | 0.002 | 100 |
| Ezrin (Phospho-Thr566) | 2.14 | 0.03 | Ezrin Y477 | 2.53 | 0.02 | 100 |
| FAK (Phospho-Ser910) | 2.04 | 0.03 | FAK Y397 | 4.18 | 0.04 | 100 |
| FLT3 (Phospho-Tyr842) | −1.20 | 0.02 | FLT3 Y452 | −1.81 | 0.03 | 79 |
| HSP27 (Phospho-Ser15) | 1.12 | 0.02 | HSP27 S15 | −4.35 | 0.01 | 67 |
| c-Jun (Phospho-Tyr170) | 4.27 | 0.04 | Jun S59 | 3.60 | 0.001 | 85 |
| MEK1 (Phospho-Thr291) | −1.22 | 0.03 | MEK1 S222 | −3.23 | 0.04 | 100 |
| MEK-2 (Phospho-Thr394) | −1.58 | 0.04 | MEK2 S220 | −1.55 | 0.01 | 100 |
| MSK1 (Phospho-Ser376) | −1.28 | 0.01 | MSK1 S366 | −3.26 | 0.008 | 100 |
| P38 MAPK (Phospho-Thr180) | −1.39 | 0.05 | P38-alpha Y181 | −1.97 | 0.02 | 100 |
| PAK1 (Phospho-Thr122) | 1.44 | 0.04 | PAK1 T212 | 5.36 | 0.001 | 80 |
| PKC delta (Phospho-Tyr52) | −1.36 | 0.04 | PKCD Y311 | −1.15 | 0.001 | 100 |
| PLCG1 (Phospho-Tyr783) | −1.20 | 0.03 | PLCG1 Y675 | −2.79 | 0.001 | 83 |
| SMAD 2 (Phospho-Thr220) | 1.48 | 0.04 | SMAD2 S245 | 3.43 | 0.01 | 100 |
| Smad2 S255 | 4.53 | 0.01 | ||||
| Smad 2/3 (Phospho-Thr8) | 1.09 | 0.03 | Smad3 T180 | 1.44 | 0.03 | |
| Src (Phospho-Tyr418) | −1.61 | 0.005 | Src Y416 | −1.44 | 0.03 | 100 |
| Src Y527 | −2.12 | 0.02 | ||||
| STAT3 (Phospho-Ser717) | 1.98 | 0.03 | STAT3 S728 | 2.44 | 0.03 | 100 |
| STAT3 Y706 | 1.99 | 0.04 | ||||
| Trk (Phospho-Tyr515) | 1.13 | 0.04 | TrKA Y490 | −1.52 | 0.02 | 84 |
| TrKA Y674 | −1.68 | 0.03 | ||||
| TrKA Y785 | −2.04 | 0.0 | ||||
| XIAP (Phospho-Ser87) | 1.17 | 0.04 | XIZP S87 | 2.12 | 0.002 | 60 |
Statistically significant (p ≤ 0.05) phosphospecific antibody array results of Salmonella Entertidis cecal samples. Four days post-infection samples were compared to non-infected control samples to find changes in infected cecal tissue over time. Antibodies due to being bound to phosphorylated protein had a statistically significant difference in fluorescent signal are shown. Fold Change Antibody Array is the change in fluorescent signal when comparing the infected samples to control samples. Homology indicates the % similarity between human and chicken at the 15 amino acid region flanking the phosphorylation residue. Fold Change Peptide Array is the change in fluorescent signal as indicated by the peptide array. N/A indicates the exact phosphorylation target residue on the antibody array was not present on the peptide array or not significantly differentially phosphorylated.
Figure 1Expression of IFN-γ mRNA in the ceca from experimental chickens with persistent colonization by Salmonella Enteritidis. The expression of IFN-γ mRNA expression was determined by quantitative RT-PCR. Data represent the fold-change in mRNA expression in the cecum from infected chickens when compared to the mRNA expression in the cecum from non-infected chickens. Data represent the mean ± SEM from three separate experiments. * = significantly different from the non-infected controls. Different lower case letters = significantly different from infected chickens at 2 days post-infection (p ± 0.05).
Real-time quantitative RT-PCR probes and primers for 28S and IFN-γ.
| RNA Target | Probe/Primer Sequence | Accession Number a | |
|---|---|---|---|
| 28S | Probe | d 5′-(FAM)-AGGACCGCTACGGACCTCCACCA-(TAMRA)-3′ | X59733 |
| F b | 5′-GGCGAAGCCAGAGGAAACT-3′ | ||
| R c | 5′-GACGACCGATTGCACGTC-3′ | ||
| IFN-γ | Probe | d 5′-(FAM)-TGGCCAAGCTCCCGATGAACGA-(TAMRA)-3′ | YO7922 |
| F | 5′-GTGAAGAAGGTGAAAGATATATCATGGA-3′ | ||
| R | 5′-GCTTTGCGTGGATTCTCA-3′ |
a Genomic DNA sequence; b Forward; c Reverse; d 5-carboxyfluorescein.